34
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Biomarkers, imaging and multifocality in intraductal papillary mucinous neoplasms: relevant for decision making?

, &
Pages 1751-1753 | Received 27 May 2017, Accepted 06 Jun 2017, Published online: 23 Aug 2017

References

  • Aronsson L , AnderssonR, AnsariD. Intraductal papillary mucinous neoplasm of the pancreas – epidemiology, risk factors, diagnosis, and management. Scand. J. Gastroenterol doi:10.1080/00365521.2017.13189481–13 (2017) ( Epub ahead of print).
  • Tanaka M , Fernandez-Del CastilloC, AdsayVet al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology12(3), 183–197 (2012).
  • Furukawa T , KubokiY, TanjiEet al. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci. Rep.1, 161 (2011).
  • Singhi AD , NikiforovaMN, FasanellaKEet al. Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts. Clin. Cancer Res.20(16), 4381–4389 (2014).
  • Permuth JB , ChoiJ, BalarunathanYet al. Combining radiomic features with a miRNA classifier may improve prediction of malignant pathology for pancreatic intraductal papillary mucinous neoplasms. Oncotarget7(52), 85785–85797 (2016).
  • Kim Y , KangM, HanDet al. Biomarker 33. J. Proteome Res.15(1), 100–113 (2016).
  • Ansari D , AronssonL, SasorAet al. The role of quantitative mass spectrometry in the discovery of pancreatic cancer biomarkers for translational science. J. Transl. Med.12, 87 (2014).
  • Fritz S , KlaussM, BergmannFet al. Pancreatic main-duct involvement in branch-duct IPMNs: an underestimated risk. Ann. Surg.260(5), 848–855 (2014).
  • Izawa T , ObaraT, TannoS, MizukamiY, YanagawaN, KohgoY. Clonality and field cancerization in intraductal papillary-mucinous tumors of the pancreas. Cancer92(7), 1807–1817 (2001).
  • Verbeke CS . Intraductal papillary-mucinous neoplasia of the pancreas: histopathology and molecular biology. World J. Gastrointest. Surg.2(10), 306–313 (2010).
  • He J , CameronJL, AhujaNet al. Is it necessary to follow patients after resection of a benign pancreatic intraductal papillary mucinous neoplasm? J. Am. Coll. Surg. 216(4), 657–665 (2013).
  • Moriya T , TraversoW. Fate of the pancreatic remnant after resection for an intraductal papillary mucinous neoplasm: a longitudinal level II cohort study. Arch. Surg.147(6), 528–534 (2012).
  • Park J , LeeKT, JangTHet al. Risk factors associated with the postoperative recurrence of intraductal papillary mucinous neoplasms of the pancreas. Pancreas40(1), 46–51 (2011).
  • Wang X , HongX, PangHet al. Selecting optimal surgical procedures for intraductal papillary mucinous neoplasm (IPMN): an analysis based on the surveillance, epidemiology, and end result registry database. Eur. J. Surg. Oncol.42(10), 1526–1532 (2016).
  • Schnelldorfer T , SarrMG, NagorneyDMet al. Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas. Arch. Surg.143(7), 639–646 (2008).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.